Trials / Unknown
UnknownNCT06006611
Risk Factors for Severe Disease in Hospitalized Patients With COVID-19 and the Effect of Azvudine Treatment: a Retrospective Cohort Study
Risk Factors for Severe Disease in Hospitalized Patients With COVID-19 and the Effect
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 4,201 (estimated)
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to explore the factors that can affect the development of severe cases in hospitalized patients with COVID-19, including basic diseases, laboratory parameters, and clinical manifestations; In addition,to explore whether Azvudine can reduce the mortality of hospitalized patients with COVID-19.
Detailed description
4201 COVID-19 patients discharged from our hospital were enrolled. Binary logistic regression analysis and ROC curve were used to investigate the role of comorbidities, laboratory parameters and clinical manifestation on progression of COVID-19 patients. We used propensity-score models conditional on baseline characteristics and Univariate Cox regression model to examine whether Azvudine can reduce the mortality of COVID-19 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azvudine | Received antiviral treatment with azvudine |
Timeline
- Start date
- 2023-08-05
- Primary completion
- 2023-10-25
- Completion
- 2023-10-30
- First posted
- 2023-08-23
- Last updated
- 2023-09-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06006611. Inclusion in this directory is not an endorsement.